Biocept, Inc.
BIOCNASDAQHealthcare
$0.43
+$0.00(+0.00%)
Market Cap$450786
P/E Ratio—
52W High$0.4349
52W Low$0.4349
Biocept, Inc. (BIOC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIOC · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 20, 2023EPS Actual
-$9.91
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 20, 2023
After Market Close
BIOC reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 12, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 8, 2024 | — | — | — | — | — | — |
| — Q4 FY2023 | Nov 20, 2023 | — | -$9.91 | — | — | — | — |
| — Q3 FY2023 | Aug 14, 2023 | — | -$3.50 | — | $0.00B | — | — |
| — Q2 FY2023 | Apr 17, 2023 | — | -$32.73 | — | $0.00B | — | — |
| ▼ Q1 FY2023 | Mar 29, 2023 | -$0.22 | -$32.57 | -14702.3% | $-0.01B | $0.00B | -407.0% |
| ▼ Q4 FY2022 | Nov 21, 2022 | -$4.80 | -$9.91 | -106.5% | $0.01B | — | — |
| ▼ Q4 FY2022 | Nov 10, 2022 | -$0.16 | -$9.31 | -5718.8% | $0.01B | — | — |
Q3 FY2024
Aug 12, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 8, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 20, 2023
EPS Actual
-$9.91
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 14, 2023
EPS Actual
-$3.50
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Apr 17, 2023
EPS Actual
-$32.73
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Mar 29, 2023Miss
EPS Actual
-$32.57
EPS Est.
-$0.22
EPS Surpr.
-14702.3%
Revenue
$-0.01B
Q4 FY2022
Nov 21, 2022Miss
EPS Actual
-$9.91
EPS Est.
-$4.80
EPS Surpr.
-106.5%
Revenue
$0.01B
Q4 FY2022
Nov 10, 2022Miss
EPS Actual
-$9.31
EPS Est.
-$0.16
EPS Surpr.
-5718.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 20, 2023 | — | $0.06 | $0.06 | +0.00% |
| — Q3 FY2023 | Aug 14, 2023 | — | $0.37 | $0.37 | -0.90% |
| — Q2 FY2023 | Apr 17, 2023 | — | $3.50 | $3.50 | +0.00% |
| ▼ Q1 FY2023 | Mar 29, 2023 | -14702.3% | $3.10 | $3.50 | +12.90% |
| ▼ Q4 FY2022 | Nov 21, 2022 | -106.5% | $8.20 | $8.40 | +2.44% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -5718.8% | $7.40 | $8.00 | +8.11% |
| ▲ Q2 FY2022 | May 23, 2022 | +33.4% | $14.40 | $14.80 | +2.78% |
| — Q2 FY2022 | Apr 6, 2022 | — | $21.70 | $21.00 | -3.23% |
Q4 FY2023+0.00%
Report Date
Nov 20, 2023
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.06
Q3 FY2023-0.90%
Report Date
Aug 14, 2023
EPS Beat/Miss
—
Price Before
$0.37
Price After
$0.37
Q2 FY2023+0.00%
Report Date
Apr 17, 2023
EPS Beat/Miss
—
Price Before
$3.50
Price After
$3.50
Q1 FY2023+12.90%
Report Date
Mar 29, 2023
EPS Beat/Miss
-14702.3%
Price Before
$3.10
Price After
$3.50
Q4 FY2022+2.44%
Report Date
Nov 21, 2022
EPS Beat/Miss
-106.5%
Price Before
$8.20
Price After
$8.40
Q4 FY2022+8.11%
Report Date
Nov 10, 2022
EPS Beat/Miss
-5718.8%
Price Before
$7.40
Price After
$8.00
Q2 FY2022+2.78%
Report Date
May 23, 2022
EPS Beat/Miss
+33.4%
Price Before
$14.40
Price After
$14.80
Q2 FY2022-3.23%
Report Date
Apr 6, 2022
EPS Beat/Miss
—
Price Before
$21.70
Price After
$21.00
Avg Beat Reaction+2.78%
Avg Miss Reaction+7.82%
Beat Rate1 / 8 quarters
Largest Move+12.90% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIOC ends December
Biocept, Inc. (BIOC) most recently reported earnings on November 20, 2023 for Q4 FY2023, posting EPS of $-9.91 (in line with the analyst consensus of —). The next BIOC earnings date is expected around September 1, 2026.
Each quarter, investors track BIOC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIOC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIOC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIOC earnings · 4 questionsBiocept, Inc.'s next earnings report is expected around September 1, 2026. BIOC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIOC historically reports after market close (AMC).
BIOC earnings datewhen is BIOC earningsBIOC next earnings datewhen does BIOC report earningsBIOC earnings calendar
▸ Source: FMP · Biocept, Inc. SEC filings · US GAAP · Biocept, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026